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ABSTRACT
Introduction Post-stroke depression (PSD) is a severe
complication of cerebrovascular stroke affecting about
one-third of stroke survivors. Moreover, PSD is associated
with functional recovery and quality of life (QOL) in stroke
survivors. Screening for PSD is recommended. There are,
however, differences in the literature on the impact of early
screening on functional outcomes. In this systematic review,
we synthesise the currently available literature regarding the
associations between timing and setting of PSD screening
and mortality, QOL and functional outcomes in stroke
survivors.
Methods and analysis We will systematically search
electronic databases including PubMed, Embase, APA
PsycINFO, Web of Science, Scopus and CINAHL from
inception to August 2021. Four reviewers will screen the
title and abstract and full-text level records identified in the
search in a blinded fashion to determine the study eligibility.
Any selection disagreements between the reviewers will
be resolved by the study investigator. Data extraction
of eligible studies will be conducted by two reviewers
using a predefined template. We will complete the quality
assessment of included articles independently by two
reviewers using the Newcastle Ottawa Scale. Eventual
discrepancies will be resolved by the principal investigator.
Ethics and dissemination Due to the nature of the study
design, ethical approval is not required. The systematic
review and meta-analysis findings will be published and
disseminated in a peer-reviewed journal. Our results will
also be disseminated through posters and presentations at
appropriate scientific conferences.
PROSPERO registration number CRD42021235993.

INTRODUCTION
Post-stroke depression (PSD) is characterised
by depressed or dysphoric mood, reduced
motivation, energy and libido, as well as
sleep disorders. It is a severe complication
of cerebrovascular stroke1 affecting about
one-third of stroke survivors.2 3 PSD appears
to be the most common psychiatric sequelae

Strengths and limitations of this study
►► Comprehensive systematic review of the associa-

tions between post-stroke depression and stroke
outcomes.
►► Rigorous methods, following the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses
guidelines, will be conducted to minimise the risk
of bias.
►► Limitations of this review include the exclusion of
papers in languages other than English and unpublished, grey materials.

of stroke, and is independently associated
with increased morbidity, mortality and
disability.4–6 PSD is also considered one of
the most significant predictors for functional
recovery and quality of life (QOL) in stroke
survivors.7 8 Stroke survivors with PSD are
more likely to commit suicide than patients
without PSD.9 10 Suicide rates are more than
double in stroke survivors compared with the
general population.11 Some stroke survivors
who subsequently developed depression, and
had a previous history of depression, reported
suicidal thoughts as early as 4 days after the
onset of stroke.12 Disability or dependence
in activities of daily living (ADLs) of patients
who have suffered a stroke may also increase
the risk of PSD13 and suicidal ideation. This
highlights an important, yet vicious cycle
between PSD and functional disabilities.
Therefore, stroke survivors with functional
disabilities should be considered at-risk for
PSD and suicidal ideation. Thus, targeted
screening for PSD and suicidal ideation is
warranted.
PSD has been consistently associated with
poorer functional outcomes1 13 (eg, inability
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However, there are differences in published studies on
the relationship between PSD and stroke recurrences.
Sibolt et al29 found that PSD was associated with increased
ischaemic stroke recurrence. Conversely, Ayerbe et al30
reported that PSD at 3 months was not associated with
higher risk of total stroke recurrence over a 5-
year
follow-up period. Another systematic review and meta-
analysis found a significant relationship between PSD
and poor functional outcomes.13 None of the available
systematic reviews have specifically investigated symptoms
of depression at the acute stroke period on all stroke-
related outcomes. Collectively, it is not clear whether
early depression screening at acute stages of stroke can
impact stroke recurrences, QOL and/or mortality.
The purpose of our review protocol is to update and
synthesise the currently available literature in order
to quantify the degree to which early onset PSD symptoms are associated with mortality, QOL and functional
outcomes in stroke survivors. The primary research aims
of this systematic review and meta-analysis are as follows:
1. To investigate if early PSD symptoms in hospitalised
patients immediately after a stroke is associated with
worse stroke-related disability within 3 months after an
acute stroke event.
2. To investigate if early PSD (at acute hospital admission or within 3 months) is associated with long-term
(>1 year) stroke-
related health outcomes (stroke-
related disability, stroke recurrence, mortality, QOL).
We hypothesise that patients with early PSD at hospital
or within 3 months, will have a substantial disability,
poorer QOL and increased mortality.

2
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METHODS AND ANALYSIS
This protocol follows the Preferred Reporting Items for
Systematic Reviews and Meta-
Analyses Protocol (PRISMA-P) guidelines.31 The PRISMA-P checklist can be found
in the online supplemental material 1. The final review
will be developed in accordance with the 2020 PRISMA
statement32 and will be informed by the Cochrane Handbook for Systematic Reviews of Interventions.33
Eligibility criteria
Inclusion criteria
Our predefined inclusion criteria, throughout the
screening process, are as follows:
(1) Uses a validated depression scale for screening after
a stroke diagnosis; (2) human subjects; (3) longitudinal/
prospective studies only; (4) English language only; (5)
peer-
reviewed, published articles only; (6) reports on
a short and/or long-
term outcome (QOL, functional
recovery [motor/disability index], mortality, recurrent
stroke/morbidity); (7) stroke diagnosis; (8) reports on
the relationship between PSD and at least one outcome
measure (see point 6); and (9) the depression measurement should be obtained at the time of stroke diagnosis
or within 3 months of the diagnosis. We will check if the
clinical diagnosis of stroke was made as per the WHO
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to perform ADLs independently) and rehabilitation
outcomes (eg, extended duration of inpatient rehabilitation).13–15 It has been hypothesised that poorer functional outcomes (mortality, limitation of daily activities,
stroke recurrences, cognitive impairment) associated
with PSD may be due to limited rehabilitation participation.13 16 For example, in a retrospective, case–control
study of 560 ischaemic stroke survivors, those with PSD
had worse mobility, longer rehabilitation length of stay
and greater insufficient response to rehabilitation efforts
(as measured by lower Barthel Index (BI) and Rivermead
Mobility Index (RMI)) than stroke survivors without
PSD.14 Furthermore, stroke survivors adequately treated
for PSD with antidepressants showed improved functional outcomes compared with antidepressant therapy
non-responders.14 However, uncertainty regarding
optimal strategies for treating PSD remains (eg, timing,
dosing, duration and pharmaceuticals).1 17 Notably, while
an independent association exists between PSD and poor
functional recovery,18 severe functional disabilities after
stroke are also related to PSD.19
The period of time immediately after a stroke event is
critical. For example, studies have shown that a substantial
functional recovery occurs within 3 months after the first
onset of stroke,20 compared with the later chronic phase.21
Rehabilitation and training can improve recovery during
the period immediately after focal brain damage. Moreover, these rehabilitation interventions are critical for the
functional restoration of patients who had a stroke.20 22 PSD
is a key factor that can influence stroke recovery. Despite
the high prevalence of PSD, and its associated risks, only
a minority of stroke survivors are adequately screened for
PSD. Despite this, optimal strategies (timing, setting and
methods) for PSD screening are currently unclear.1 23 The
risk of depression in stroke survivors is high immediately
after the acute stroke, especially within the 3 months after
a stroke,24 during which the prevalence is estimated to be
33%. Interestingly, nearly half of those who had depression
in the first 3 months of acute stroke recovered at 1 year.24
Routine screening for PSD in at-risk patients (eg, those
with severe functional disabilities and a history of depression) in the early stroke recovery period has been shown
to reduce the risk of PSD.13 However, other studies did
not find supportive evidence for PSD screening and stroke
outcomes.25 26 Nevertheless, randomised controlled clinical trials show that screening and collaborative care for
depression treatment, can improve functional outcomes
in chronic medical conditions, including stroke.27 The
American Heart Association/American Stroke Association recommends screening for PSD in patients after
acute stroke, as well as further research into the effect of
PSD on all outcomes, including QOL.1 To optimise the
care for patients who had a stroke, appropriate processes
should be established before screening occurs to assure
correct PSD diagnosis, adequate treatment and routine
follow-up.1
A meta-analysis revealed an increased risk of mortality
in those with PSD,28 where the estimated HR was 1.59.

Open access

Exclusion criteria
Our predefined exclusion criteria, throughout the
screening process, are as follows:
(1) Studies involving animals; (2) conference abstracts,
posters or papers; (3) editorials/letter to the editor, unless
it reports original research data that meets our predefined
inclusion criteria; (4) patients with any primary psychiatric illness, except for anxiety/depression; (5) patients
with dementia, epilepsy, cancer or multiple sclerosis; (6)
patients with neurological or neurodegenerative conditions, except for stroke/neurovascular; (7) reviews of
any kind; (8) questionnaire validation studies; (9) case
studies; (10) randomised controlled trials (RCTs); (11)
paediatric studies (samples that include patients under
the age of 18 years); (12) studies assessing the effectiveness of medication; (13) protocol papers; (14) studies
with retrospective design; (15) studies that have less than
1-year follow-up period; and (16) theses and dissertations.
Information sources and search strategy
A comprehensive search of peer-reviewed literature from
six electronic databases will be conducted from their
inception through to August 2021. The following medical
and health sciences databases will be included: PubMed
(NLM), Embase (Elsevier), APA PsycINFO (EBSCOhost), Scopus (Elsevier), Web of Science (Clarivate) and
CINAHL (EBSCOhost). A preliminary search string to
support the development of the research question and
preset inclusion and exclusion criteria, was conducted in
February–March 2021. The search strategy was developed
by a medical librarian who is specialised in the conduct of
systematic reviews (LÖ). PubMed and PubMed’s Medical
Subject Headings (MeSH) was used to systematically
identify relevant search terms and synonyms for review
and further suggestions by a subject specialist (SSe). The
pre-search in PubMed will be adapted to, and performed
in, all six selected databases. All keywords will be searched
in a combination of the fields: ‘title’, ‘abstract’ and in
‘MeSH’/‘thesaurus’. We will limit the search to English
papers only. No additional filters or geographical limitations will be used to ensure the best possible literature
Selvaraj S, et al. BMJ Open 2021;11:e050451. doi:10.1136/bmjopen-2021-050451

inclusion. Systematic hand screening of the reference
lists of the included papers identified by the search will
be conducted independently by two reviewers. A search
log, with search technical specifications, as well as results
and notes for all databases included in the search, will
be appended to the review to support the appraisal and
reproduction of the search. The literature search will
be repeated before completing the data extraction, and
potential new studies published during the work process
will be added to the result. The details of the preliminary
search preformed in PubMed is available in the (online
supplemental material 2).
Data management
The result from the database search will be uploaded to
the systematic review software, Covidence.36 Automatic
deduplication and screening will be conducted in the software. The finally selected references will be exported to
a reference management software to enable manuscript
preparation. Covidence will also support the update of
the search before publishing by a re-upload and deduplication of the complete result from all databases. This will
ensure blinded screening of all additional back-file and
new records added since the initial search in May 2021.
Selection of studies
All unique records identified in the database search
will be screened for eligibility against the predefined
inclusion and exclusion criteria by four independent
reviewers, as follows: TA and HA will conduct the initial
title and abstract screening. TM and IG will screen the
papers selected for full-text review. After each screening
module, eventual conflicts identified by the software will
be resolved by a fifth reviewer (SSe). All stages of the
screening and selection processes in Covidence follow
the PRISMA workflow.32 The screening processes and
blinding will be predefined in the software settings based
on the authors' responsibilities.
The search result, deduplication, screening and selection process, including reasons for study exclusion, will be
documented in a PRISMA (2020) flow diagram. Cabells
Predatory Reports37 will be consulted to verify that eventual open access papers selected are not published in
possible predatory journals.
Data extraction
An extraction template will be used to extract relevant
data from each of the included studies. The template will
be developed by the team statistician (RS) and the principal investigator (SSe). The data extraction template will
be piloted on five articles initially and adjusted, if necessary. Information about population characteristics, length
of follow-up, depression scale used, time of screening for
depression, stroke disability ratings, rehabilitation length
of stay, mobility status as well as QOL scales and scores
will be documented. The effect size/measure of association between PSD screening and the outcome variables
of interest, along with 95% CIs will also be extracted. Two
3
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definition of stroke: ‘rapidly developing clinical signs of
focal (or global) disturbance of cerebral function, with
symptoms lasting 24 hours or longer or leading to death,
with no apparent cause other than of vascular origin’.
Therefore we will exclude transient ischaemic attack
and stroke symptoms caused by subdural haemorrhage,
tumours, poisoning or trauma.34 We will include validated
depression instruments35 including Diagnostic and Statistical Manual of Mental Disorders, International classification of Diseases and specific scales such as Center for
Epidemiologic Studies Depression Scale, Patient Health
Questionnaire, Hospital Anxiety and Depression Scale
and Hamilton Depression Rating Scale, Beck Depression
Inventory, Stroke Aphasia Depression Questionnaire,
Aphasia Depression Rating Scale, Geriatric Depression
Scale.
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Quality assessment of individual studies
Two reviewers will independently assess the quality of
evidence and the risk of bias of all eligible studies using
the Newcastle Ottawa Scale. Eventual disagreements
between the reviewers will be discussed with the principal
investigator (SSe) until a consensus is reached.
Data analysis and synthesis
The systematic review will identify and report the number
of qualifying articles and provide an overall summary.
Information surrounding the sample size, population and
outcomes of interest will be compared across the studies.
Articles that contain appropriate statistical information
for meta-analysis will be assessed by the team statistician
(RS). The meta-
analysis will calculate a pooled prevalence ratio/OR/HR and 95% CI for each outcome variable of interest. Specific outcomes that will be evaluated
in the present study will include stroke disability scales
(BI, Modified Rankin Scale, RMI), QOL (short form 36;
stroke-specific QOL, Euro-QOL) and mortality (dichotomous). The lower bound of studies to be included in
any given meta-analysis is two.38 Analyses will, however,
include as many studies that meet our predefined inclusion/exclusion criteria. Finally, we will perform meta-
regression to account for the influence of stroke severity
(National Institutes of Health, Glasgow Coma Scale),
type of stroke (ischaemic vs haemorrhagic) and length of
follow-up (months).
To account for potential sources of heterogeneity,
we will use random effects models in all analyses. Both
a narrative and pooled prevalence will be reported. A
forest plot will be used to provide a visual summary of the
point estimate and 95% CI for each study and the overall
pooled effect. Visual inspection of funnel plots, with trim
and fill as well as Egger’s test of asymmetry, will be used
to identify sources of bias. Individual study influence will
be evaluated via leave-one-out jackknife sensitivity analysis, whereby the overall pooled effect is calculated while
omitting each study in turn.
Analyses will be conducted using the package metafor39
in the R Statistical Computing Environment40 by the team
statistician (RS). We will assess confidence in estimates by
evaluating sources of bias in the main patient outcomes.
We will follow the Grading of Recommendations Assessment, Development, and Evaluation guidelines.40

include grey literature sources. However, our comprehensive search strategy covers six major databases that
will provide relevant, published, high-
quality papers.
Although RCTs and retrospective studies can provide
additional insight, we decided not to include these in our
review for the following reasons. First, when we evaluated
our pilot searches, we found that the range of interventions studied in RCTs was extremely variable. Moreover,
controlling for outcomes are difficult. Furthermore, RCTs
are typically shorter time-framed which is not aligned
with our aim of investigating the early depression symptoms and its impact on long-term stroke outcome(s). We
excluded retrospective studies, due to bias associated with
these types of studies including selection and recall bias.
Furthermore, it is difficult to ascertain temporal relationships between depression and stroke outcomes with retrospective studies.
Review status
A preliminary search was performed in PubMed with the
start in February 2021 and the result was updated in July
2021 (see online supplemental material 2). The review is
set to start in May 2021.
Potential amendments
To avoid reporting bias of the review, we do not intend to
modify the protocol. However, if necessary, any changes
to the time frame or process of the review will be reported
through updates in the online registered PROSPERO
protocol.
Patient and public involvement
No patients or members of the public are involved in this
study.

ETHICS AND DISSEMINATION
Our institutional ethics board policies exempts ethical
approval for systematic reviews. The review results will be
published in a peer-reviewed journal and disseminated
through abstracts, posters and oral presentations at relevant scientific conferences.

Strengths and limitations
The strength of the protocol is the study design including
the longitudinal cohort design to focus on early post-
stroke period. Our review will also employ comprehensive search strategies, compliance to PRISMA guidelines
for systematic reviews and our protocol is also registered
with the international database, PROSPERO. We also
acknowledge the following limitations. First, we will not

Author affiliations
1
Louis Faillace, MD, Department of Psychiatry, McGovern Medical School at the
University of Texas Health Science Center at Houston, Houston, Texas, USA
2
Institute for Stroke and Cerebrovascular Disease, University of Texas Health
Science Center at Houston, Houston, Texas, USA
3
College of Natural & Health Sciences, Zayed University, Abu Dhabi, UAE
4
Cizik School of Nursing, University of Texas Health Science Center at Houston,
Houston, Texas, USA
5
Department of Cognitive Science, United Arab Emirates University, Al Ain, UAE
6
Department of Psychology, College of Natural & Health Sciences, Zayed University,
Abu Dhabi, UAE
7
Department of Research, Cizik School of Nursing, University of Texas Health
Science Center at Houston, Houston, Texas, USA
8
Department of Neurology, McGovern Medical School at the University of Texas
Health Science Center at Houston, Houston, Texas, USA
9
National Medical Library, College of Medicine and Health Sciences, United Arab
Emirates University, Al Ain, UAE

4

Selvaraj S, et al. BMJ Open 2021;11:e050451. doi:10.1136/bmjopen-2021-050451

BMJ Open: first published as 10.1136/bmjopen-2021-050451 on 17 August 2021. Downloaded from http://bmjopen.bmj.com/ on August 29, 2021 by guest. Protected by copyright.

reviewers will extract the information independently and
any discrepancies will be resolved by the primary study
investigator (SSe).
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